Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
copanlisib
Class :
Antineoplastics and PI3K Inhibitors
Brand Name :
No Data Available.
Synonyms :
copanlisib
Class :
Antineoplastics and PI3K Inhibitors
Adult:
Dosage Forms & Strengths
Injection-lyophilized powder for reconstitution
60 mg
60
mg
Solution
Intravenous (IV)
every week
1
hr
An intermittent schedule like 21 days on and 1 week off has to be followed Continue the therapy until disease progression or unacceptable toxicity occurs
it may decrease therapeutic effect of vaccines (inactivated)
in may increase the adverse or toxic effect of vaccines (live)
may enhance the serum concentration of CYP3A4 inhibitors
when both drugs are combined, there may be an increase in the effect of immunosuppressants
nafcillin will decrease the effect of action of copanlisib by affecting enzyme CYP3A4 metabolism.
CYP3A strong enhancers of the small intestine may reduce the bioavailability of copanlisib
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of copanlisib can be reduced by butabarbital
aminosalicylic acid derivatives
it may increase the effect of myelosuppressive agents
it may decrease the therapeutic effect of antidiabetic agents
when both drugs are combined, there may be an increase in the adverse or toxic effects of myelosuppressive agents
copanlisib: they may diminish the serum concentration of CYP3A4 Inducers
copanlisib: they may diminish the serum concentration of CYP3A4 Inducers
copanlisib: they may diminish the serum concentration of CYP3A4 Inducers
copanlisib: they may diminish the serum concentration of CYP3A4 Inducers
copanlisib: they may diminish the serum concentration of CYP3A4 Inducers
it may enhance the metabolism when combined with oxcarbazepine
copanlisib: they may enhance the serum concentration of CYP3A4 Inhibitors
copanlisib: they may enhance the serum concentration of CYP3A4 Inhibitors
copanlisib: they may enhance the serum concentration of CYP3A4 Inhibitors
copanlisib: they may enhance the serum concentration of CYP3A4 Inhibitors
copanlisib: they may enhance the serum concentration of CYP3A4 Inhibitors
When copanlisib is used together with ridaforolimus, this leads to enhanced concentration serum of copanlisib
when both drugs are combined, the risk or severity of adverse effects increases
the effect of copanlisib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A4 inhibitors increase the concentration of copanlisib in serum
The phosphatidylinositol-3-kinase (PI3K) signalling pathway is linked to both chemotherapeutic drug resistance and cell survival and proliferation.
The class I PI3K inhibitor copanlisib shows selective activity against the PI3K-α and PI3K-δ isoforms that are expressed in B cells that are malignant.
Frequency defined
>10%
Any grade
Decreased neutrophils
Hypertriglyceridemia
Hypophosphatemia
Leukopenia
Decreased hemoglobin and lymphocytes
Decreased white blood cells
Decreased platelets
Thrombocytopenia
Grade 3
Hyperglycemia
Decreased WBCs
Hyperphosphatemia
Leukopenia
Lower respiratory tract infections
Hypertension
Hyperuricemia
Grade 4
Leukopenia
Neutropenia
1-10%
Mucosal inflammation
Pneumonitis
None
None
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Copanlisib is a kinase inhibitor that has pro-apoptotic and anti-tumor properties in a variety of tumor cell lines and xenograft models.
Plasma glucose levels are increased by copanlisib.
PI3K isoforms are frequently overexpressed in follicular lymphoma and other B-cell malignancies.
Copanlisib was voluntarily discontinued for follicular lymphoma in November 2023.
Thus, route of administration is not reported.
Patient Information Leaflet
Generic Name: copanlisib (Rx)
Pronounced: ko-pan-li-sib
Why do we use copanlisib?
Adult patients with relapsed follicular lymphoma (FL) who have had at least two previous systemic treatments may be treated with copanlisib.
The decision of withdrawal was supported by the recently revised CHRONOS-4 research, which demonstrated that progression-free survival was not enhanced by the addition of copanlisib to conventional immunochemotherapy regimens.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
